
Netherlands-based drugmaker UniQure NV QURE.O looks to capitalize on its soaring share price by raising equity
Its U .S.-listed shares on Weds finished up ~248% at $47.50 after co said its experimental gene therapy significantly slowed Huntington's disease progression in early-to-mid-stage trial
It also announced early Weds it secured a $175 mln loan from Hercules Capital HTGC.N to support the potential U.S. launch of AMT-130
After the bell, co commences $200 mln share offering, including pre-funded warrants
Leerink Partners, Stifel, Van Lanschot Kempen and Guggenheim Secs are bookrunning managers for offering
QURE has ~54.9 mln shares outstanding for about $2.6 bln current market cap
U.S.-listed shares up 3.6% at $49.20 in extended trading